Close
Back to AKCA Stock Lookup

(AKCA) – PRNewswire

Oct 30, 2020 07:00 AM Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
Oct 12, 2020 09:00 AM Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
Aug 31, 2020 06:55 AM Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Aug 29, 2020 04:00 AM Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
Aug 29, 2020 03:30 AM Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
Aug 24, 2020 07:00 AM Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
Aug 18, 2020 07:00 AM Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
Aug 13, 2020 07:00 AM Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Aug 5, 2020 07:00 AM Ionis reports second quarter 2020 financial results and recent business achievements
Aug 4, 2020 04:05 PM Akcea Reports Financial Results and Highlights for Second Quarter 2020
Jul 22, 2020 07:00 AM Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Jul 21, 2020 07:00 AM Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
Jul 20, 2020 07:00 AM Akcea Appoints New Senior Vice President, Global Medical Affairs
Jul 9, 2020 07:00 AM Akcea Announces Appointment of New Chief Medical Officer
Jun 29, 2020 07:00 AM Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
Jun 17, 2020 07:00 AM Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 9, 2020 07:00 AM Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
Jun 8, 2020 07:00 AM Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
Jun 1, 2020 07:00 AM Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
May 18, 2020 07:00 AM Akcea Announces Appointment of New Chief Financial Officer
May 14, 2020 04:05 PM Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
May 7, 2020 07:00 AM Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
May 6, 2020 07:00 AM Ionis reports first quarter 2020 financial results and recent business achievements
May 5, 2020 04:05 PM Akcea Reports Financial Results and Highlights for First Quarter 2020
Feb 26, 2020 07:00 AM Ionis provides fourth quarter and full year 2019 financial results
Jan 22, 2020 07:05 AM Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Nov 6, 2019 07:00 AM Ionis provides third quarter financial results and improved 2019 guidance
Aug 7, 2019 07:00 AM Ionis Reports Second Quarter 2019 Financial Results

Back to AKCA Stock Lookup